Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion.
about
Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathologic myopiaAnti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusionAnti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusionAnti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusionAnti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusionAnti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusionRetinal vein occlusion: pathophysiology and treatment optionsThe related transcriptional enhancer factor-1 isoform, TEAD4(216), can repress vascular endothelial growth factor expression in mammalian cellsAnterior chamber depth and angle-closure glaucoma after central retinal vein occlusionRETINAL BLOOD FLOW AFTER INTRAVITREAL BEVACIZUMAB IS A PREDICTIVE FACTOR FOR OUTCOMES OF MACULAR EDEMA ASSOCIATED WITH CENTRAL RETINAL VEIN OCCLUSION.Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data.Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits.Vitrectomy may prevent the occurrence of diabetic macular oedema.Central Retinal Vein Occlusion in Younger Swedish Adults: Case Reports and Review of the Literature.Neovascular glaucomaTransient inhibition of transforming growth factor-beta1 in human diabetic CD34+ cells enhances vascular reparative functions.Role of vascular endothelial growth factor in the breakdown of the blood-aqueous barrier after retinal laser photocoagulation in pigmented rabbits.Antiangiogenic therapy for ischemic retinopathies.Lens subluxation after plasmin and SF6 injections in rabbit eyes.Endoglin (CD105) expression in the development of haemorrhoids.Differences in aqueous concentrations of cytokines in macular edema secondary to branch and central retinal vein occlusionEarly peripheral laser photocoagulation of nonperfused retina improves vision in patients with central retinal vein occlusion (Results of a proof of concept study).A meta-analysis of anti-vascular endothelial growth factor remedy for macular edema secondary to central retinal vein occlusionRetinal vein occlusion and macular edema - critical evaluation of the clinical value of ranibizumab.Targeted photocoagulation of peripheral ischemia to treat rebound edema.Clinical and histological characteristics of canine ocular gliovascular syndrome.Ranibizumab for macular edema secondary to retinal vein occlusion: a meta-analysis of dose effects and comparison with no anti-VEGF treatment.Vascular endothelial growth factor biology: clinical implications for ocular treatmentsIntravitreal steroid and anti-vascular endothelial growth agents for the management of retinal vein occlusion: evidence from randomized trials.Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab.Management of retinal vascular diseases: a patient-centric approach.Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia.A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG study: study protIntraocular cytokines in retinal vein occlusion and its relation to the efficiency of anti-vascular endothelial growth factor therapy.Pegaptanib sodium for ocular vascular disease.Effects of intravitreal bevacizumab on reduced visual acuity and macular thickness secondary to branch retinal vein occlusion.Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion.Silver nanoparticles inhibit VEGF-and IL-1beta-induced vascular permeability via Src dependent pathway in porcine retinal endothelial cells.Bevacizumab (avastin) in ocular processes other than choroidal neovascularization.Neovascular events in eyes with central retinal vein occlusion undergoing serial bevacizumab or ranibizumab intravitreal injections: a retrospective review
P2860
Q24194332-5928A87D-26DA-48D9-8FC6-6E8B14E5A1D0Q24194783-D3692D23-53EA-4A17-A226-DBA9D89470E2Q24201821-B77711FD-4557-43D4-BEB9-AB50F6EA78CCQ24234625-65396A35-DC5F-44B7-B4F7-306B5A59A710Q24234750-906B3F77-E817-4646-B9E5-2A1BE545DD67Q24242868-79F54036-7F4B-4D9D-AF5D-A75F50A46834Q24596993-9BF72CA6-01FD-4B44-A776-CFB5D54D401EQ28728051-78CFC579-AA68-4080-8831-863575EA3D20Q30382208-352BCC22-5CAD-4953-8114-E44B40CC06E4Q30490830-AF541934-AF54-4164-80ED-4F7571D9D192Q31163540-A4A1B0A0-3210-4F95-BF40-2F6A905D43B6Q33335166-FD0801CC-1714-4E53-A6AA-09D580580C1BQ33457562-3853F1E9-A610-473F-8B02-D10E6CA7B386Q33737235-4C658034-37A8-4D4A-A3EE-C74FC3114365Q33855412-43233AAC-4CA1-4C02-9DE5-B631D697290BQ34024355-74D88C61-4B0C-4E48-92BD-A73F4105C68AQ34051527-8EB030CA-F0FA-4AE8-A85B-B81FE67A154DQ34295974-C550423C-7AD0-4B84-B988-97E7F117837EQ34514583-99604772-F551-426B-ADDB-806A179DECA9Q34545010-A634959D-EBB0-4981-9225-CAE51FB8732BQ34826956-110EC160-55F4-4EC1-9B82-32783B86A97AQ35068919-2389978B-4239-4FF8-9702-3B7F97C60EE0Q35077598-9D6700F9-D921-46FB-A4F8-AED9D0FCADE0Q35089799-BB2D0302-A677-434B-BCC4-28BF26DD9E40Q35105168-ABB880F1-28EE-48A8-898A-5B9663D5BCA5Q35235652-DE2D74DC-78F1-4CCA-810B-D5D71ECA08CAQ35238074-AE71A161-5365-446E-8CB9-C619BF00F68CQ35762769-3333142E-AB9C-4F69-A111-7FD3C97BBE34Q35769968-9560E8F0-C1B5-4B12-BD2C-43CFE5F6F49AQ35872579-492A092F-4663-4A13-BA6C-007A0A05815FQ35909406-B9F59150-B77C-4BC7-80FC-DD90C35BB78CQ36224527-72FC1B28-2111-4772-A54D-0837E9CEE718Q36311337-5BD33DCB-2908-4289-A407-9E7FA8AEFB8AQ36667368-C4C53CF9-852F-4931-8530-77CEE07B7DBFQ36977426-D74C866F-2E29-4359-BFA4-C8E3F8A218DEQ37170006-5D2EAEAF-C980-4937-B119-5766F4F89F95Q37236106-C4BE1DE8-AF92-4403-A79F-6FB1496BDAEEQ37418304-A4346E33-475E-4937-AA6B-1525245E4DCFQ37468754-1922E70A-2E05-47CC-8BE9-9BBD66B4A590Q38364703-1D030200-A2CB-4FE1-9397-DEE197EF56CF
P2860
Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Correlation of increased vascu ...... chemic central vein occlusion.
@ast
Correlation of increased vascu ...... chemic central vein occlusion.
@en
type
label
Correlation of increased vascu ...... chemic central vein occlusion.
@ast
Correlation of increased vascu ...... chemic central vein occlusion.
@en
prefLabel
Correlation of increased vascu ...... chemic central vein occlusion.
@ast
Correlation of increased vascu ...... chemic central vein occlusion.
@en
P2093
P1433
P1476
Correlation of increased vascu ...... chemic central vein occlusion.
@en
P2093
G Brian Wisdom
George J Allen
Ian A Cree
Ian Zachary
John F Martin
Philip G Hykin
Shelley R Boyd
Usha Chakravarthy
P304
P356
10.1001/ARCHOPHT.120.12.1644
P407
P577
2002-12-01T00:00:00Z